<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2024-02-08T16:27:46.079Z"
        cq:lastModifiedBy="reference-adjustment-service"
        cq:template="/conf/menarini-berlinchemie/settings/wcm/templates/menarini---details-news"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="Menarini Ricerche announces publication of pre-clinical data of the first-in-class antibody-drug conjugate MEN1309/OBT076,"
        jcr:uuid="01ba32fa-5e35-469a-8438-6883d86cbab7"
        sling:resourceType="menarinimaster/components/page"
        dnnNewsIdentifier="8a1c191b-1720-40aa-88de-c68d8076ed34-915">
        <root
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    jcr:primaryType="nt:unstructured"
                    jcr:title="News &amp; Medien"
                    sling:resourceType="menarinimaster/components/internalheader"
                    altValueFromDAM="{Boolean}false"
                    imageFromPageImage="{Boolean}false"
                    titleFromPage="{Boolean}false"/>
                <section
                    jcr:lastModified="{Date}2023-05-23T15:09:53.441Z"
                    jcr:lastModifiedBy="a.messori@adiacent.com"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/section">
                    <wrapper
                        jcr:lastModified="{Date}2023-05-23T15:11:01.995Z"
                        jcr:lastModifiedBy="a.messori@adiacent.com"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/wrapper">
                        <breadcrumb
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/breadcrumb"/>
                    </wrapper>
                </section>
                <container
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-berlinchemie/de/menarini-group-news"
                        structureStart="{Long}0">
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:styleIds="[1684742346871]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <news_data
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/news_data"
                            newsDate="{Date}2019-06-28T09:11:00.000Z">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="9"/>
                            </cq:responsive>
                        </news_data>
                        <title
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2023-06-07T15:16:13.835Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2"/>
                        <image
                            jcr:lastModified="{Long}1707398380261"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/image"
                            displayPopupTitle="true"
                            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-INTRO-Menarini-Ricerche_per_news.jpg"
                            imageFromPageImage="{Boolean}false"
                            isDecorative="true"
                            linkTarget="_self"
                            titleValueFromDAM="false">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="2"
                                    width="4"/>
                                <phone
                                    jcr:primaryType="nt:unstructured"
                                    offset="1"
                                    width="10"/>
                            </cq:responsive>
                        </image>
                        <spacer
                            jcr:lastModified="{Date}2023-06-07T15:17:27.212Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="40"/>
                        <text
                            jcr:lastModified="{Long}1707398380263"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/text"
                            text="&lt;style type=&quot;text/css&quot;>.ArticleDetailsTitle { margin-bottom:0px; }&#xa;&lt;/style>&#xa;&lt;h1>currently in Phase I clinical development&lt;/h1>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: center;&quot;>&lt;strong>&lt;span>&lt;img alt=&quot;&quot; src=&quot;/Portals/31/Images/notizie/Menarini-Ricerche.jpg&quot; style=&quot;text-align: center;&quot; />&lt;/span>&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: center;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;strong>&lt;span>Pomezia, Italy, June 28, 2019 - Menarini Ricerche today announced the publication of the results of a non-clinical study describing the characterization of the anti-CD205 Antibody-Drug Conjugate (ADC) &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/MEN1309&quot;>MEN1309&lt;/a>/OBT076. These findings have been published by the &lt;a href=&quot;http://mct.aacrjournals.org/content/early/2019/06/21/1535-7163.MCT-18-0624&quot; target=&quot;_blank&quot;>journal Molecular Cancer Therapeutics&lt;/a>&lt;/span>&lt;/strong>&lt;strong>&lt;span>&lt;a href=&quot;http://mct.aacrjournals.org/content/early/2019/06/21/1535-7163.MCT-18-0624&quot; target=&quot;_blank&quot;>.&lt;/a> &lt;/span>&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;span>&amp;nbsp;&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>The study showed that CD205, a transmembrane glycoprotein, is robustly expressed in a variety of solid malignancies, such as pancreatic and bladder tumors, as well as triple negative breast cancer (TNBC). In these settings, &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/MEN1309&quot;>MEN1309&lt;/a>/OBT076 showed substantial &lt;em>in vitro&lt;/em> antitumor activity. These results were confirmed &lt;em>in vivo &lt;/em>&lt;span>where&lt;/span> &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/MEN1309&quot;>MEN1309&lt;/a>/OBT076 demonstrated&lt;strong> potent antitumor activity&lt;/strong> in TNBC, pancreatic, and bladder xenografts and patient-derived PDX models, resulting in &lt;strong>durable responses and complete tumor regressions.&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;span>&amp;nbsp;&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&amp;ldquo;These non-clinical data show the promising activity of &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/MEN1309&quot;>MEN1309&lt;/a>/OBT076 in solid tumors expressing CD205, thus supporting the clinical development of MEN1309, which is being evaluated in the phase I SHUTTLE study&amp;rdquo; (NCT03403725), said &lt;strong>Monica Binaschi, PhD, Director of the Preclinical and Translational Sciences Department of Menarini Ricerche&lt;/strong>. &amp;ldquo;Moreover, these results provide a strong rationale for one of the key elements of the clinical development strategy of &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/MEN1309&quot;>MEN1309&lt;/a>/OBT076, represented by the &lt;strong>specific targeting of patients with tumors&lt;/strong> expressing CD205 as confirmed by an appropriate assay developed in-house. The published study represents an example of fruitful scientific collaboration between academic centers of excellence in oncology research and industry, involving Joaquin Arribas and his team at the Vall D&amp;rsquo;Hebron Institute of Oncology (VHIO) in Barcelona, as well as our partner Oxford BioTherapeutics (OBT)&amp;rdquo;.&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;strong>&lt;span style=&quot;color: black;&quot;>About &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/MEN1309&quot;>MEN1309&lt;/a>/OBT076&lt;/span>&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;span style=&quot;color: black;&quot;>MEN1309/OBT076, is an ADC comprising a fully human antibody targeting CD205, coupled to the DM4 toxin. MEN1309/OBT076 is in development for a number of CD205-driven tumors. &lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;span>MEN1309/OBT076 is currently in development with a multicenter first-in-human clinical study in major European oncology centers in Italy, Spain, Belgium and UK, (NCT03403725) to evaluate the activity of the antibody in the treatment of metastatic solid cancers, &lt;/span>&lt;span style=&quot;color: black;&quot;>including gastric cancer, triple-negative breast cancer, bladder cancer and pancreatic cancers as well as non-Hodgkin lymphoma (NHL). &lt;/span>&lt;span>This clinical trial follows a precision oncology approach, key component of Menarini&amp;rsquo;s strategy, recruiting only patients positive for the expression of the therapeutic target CD205. Dose-Escalation phase I clinical trial is starting in the United States in highly experienced academic centers under the sponsorship of OBT.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&amp;nbsp;&lt;/p>"
                            textIsRich="true"/>
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </container>
                </container>
            </container>
        </root>
        <cq:featuredimage
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="{Boolean}false"
            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-INTRO-Menarini-Ricerche_per_news.jpg"/>
    </jcr:content>
</jcr:root>
